Schizophrenia Clinical Trials in Philadelphia

Showing 21-40 of 149 trials

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01490086

The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.

Acute SchizophreniaSchizoaffective Disorder

Reviva Pharmaceuticals234 participantsStarted Dec 2011

Philadelphia, Pennsylvania, United States • Bangalore, India • Chennai, India +12 more locations

COMPLETEDPhase 3< 1 mile

A Study of Paliperidone Palmitate 6-Month Formulation

NCT03345342

The purpose of this study is to demonstrate that injection cycles consisting of a single administration of paliperidone palmitate 6-month (PP6M) are not less effective than 2 sequentially administered injections of paliperidone palmitate 3-month PP3M) (350 or 525 mg eq.) for the prevention of relapse in participants with schizophrenia previously stabilized on corresponding doses of paliperidone palmitate 1-month (PP1M) (100 or 150 mg eq.) or PP3M (350 or 525 mg eq.).

Schizophrenia

Janssen Research & Development, LLC841 participantsStarted Nov 2017

Rogers, Arkansas, United States • Anaheim, California, United States • Costa Mesa, California, United States +135 more locations

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

A Study of Paliperidone Palmitate 6-Month Formulation

Schizophrenia Trials in Other Cities

Building Employment Skills Through Therapy for Veterans

ACP-104 in Acutely Psychotic Subjects With Schizophrenia

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

ERG Components in Schizophrenia and Bipolar Disorder Type I

7-week Study With CT-155 in People With Schizophrenia

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

Other Conditions in Philadelphia